Stages Archives - Page 2 of 20

Small Molecule Reactivator of p53 Y220C Mutant

Mutant p53 is one of the most attractive targets for new anti-cancer drugs. Although traditionally regarded as difficult to drug,...

Strategies for Screening and Characterizing Targeted Covalent Inhibitors

With advancements in drug design, there is resurging interest in drugs that form covalent bonds with their targets, often referred...

Pharmacodynamic and Pharmacokinetic Profile of a Novel GLP-1 Receptor Biased Agonist

Glucagon‐like peptide‐1 (GLP-1) receptor agonists have emerged as promising therapeutic options for addressing type‐2 diabetes, obesity, and related conditions. However,...

Preclinical Evaluation of the SARS-CoV-2 Mpro Inhibitor RAY1216

WuXi AppTec scientists contributed to a research article in the journal Nature Microbiology, which characterized a peptidomimetic inhibitor of the...

Discovery Platform for Targeted Protein Degradation

In the last decade, targeted protein degradation (TPD) technology has become one of the most promising methods to remove specific...

In Silico Drug Discovery Platform

WuXi AppTec offers a comprehensive platform of in silico drug discovery services to accelerate the process of hit finding and...

Creating a Biological Switch Using DEL Technology

In addition to identifying chemical starting points for early drug discovery processes, DNA-encoded library (DEL) technology has now expanded to...

Integrated Screening in Hit Identification

Despite the availability of modern screening technologies, identification and optimization of hits against poorly druggable targets remains a significant challenge...

Heme Oxygenase-1-Targeting Molecules

WuXi AppTec scientists published a study in the open access archive ChemRxiv describing the discovery of highly selective, novel, heme...

Knowledge Library